Percutaneous transluminal angioplasty (PTA) is the most common therapy used to treat dialysis patients with an occluded arteriovenous fistula (AVF) or arteriovenous graft (AVG). AVF or AVG hemostasis after PTA is time consuming, and it may be complicated with acute thrombosis of the AVF or AVG and re-bleeding from the puncture site. In this study, we prospectively studied 145 hemodialysis patients with occluded AVF or AVG using a modified purse-string suture with short tubing tourniquet technique for hemostasis following PTA, during which we used heparin and urokinase infusion. The results indicated that the modified technique for hemostasis of AVF orAVG was effective and safe in achieving immediate hemostasis withoutmanual compression in all patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236565 | PMC |
| http://dx.doi.org/10.6515/ACS.201811_34(6).20180622A | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hand acceleration time (HAT) as a diagnostic tool in the assessment of haemodialysis access-induced distal ischaemia (HAIDI): study protocol for a prospective cohort study in the Barcelona south metropolitan area.
BMJ Open
January 2025
Bio Heart Cardiovascular Diseases Research Group, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Barcelona, Spain.
Introduction: Chronic hand ischaemia may affect some haemodialysis patients with an arteriovenous fistula (AVF) or graft (AVG), a condition known as haemodialysis access-induced distal ischaemia (HAIDI). Duplex ultrasonography (DUS) can provide comprehensive insights into anatomical and perfusion properties, and measuring the hand acceleration time (HAT) has been demonstrated to be sensitive within the framework of chronic upper limb ischaemia.
Methods And Analysis: This single-centre, prospective cohort study will involve adult end-stage renal disease (ESRD) patients requiring either AVF or AVG for haemodialysis.
A soft thermal sensor for the continuous assessment of flow in vascular access.
Nat Commun
January 2025
Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL, USA.
Hemodialysis for chronic kidney disease (CKD) relies on vascular access (VA) devices, such as arteriovenous fistulas (AVF), grafts (AVG), or catheters, to maintain blood flow. Nonetheless, unpredictable progressive vascular stenosis due to neointimal formation or complete occlusion from acute thrombosis remains the primary cause of mature VA failure. Despite emergent surgical intervention efforts, the lack of a reliable early detection tool significantly reduces patient outcomes and survival rates.
View Article and Find Full Text PDFHemodialysis Arteriovenous Graft and The Effect of Obesity on Patency. A Retrospective Study.
Ann Vasc Surg
December 2024
Sheffield Kidney Institute, Northern General Hospital, Sheffield, United Kingdom.
Background: Obesity is growing in the hemodialysis (HD) population. Few scholars report variable effects of increased body mass index (BMI) on native fistula. Reports on obesity effects on arteriovenous graft (AVG) patency are lacking.
View Article and Find Full Text PDFAdvancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency.
Int J Mol Sci
November 2024
Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Chronic kidney disease (CKD) affects more than 10% of the world's population. Hemodialysis, along with peritoneal dialysis and renal transplant, is one of the renal replacement therapies offered to patients with CKD/end-stage renal disease (ESRD). To proceed with hemodialysis, vascular access is required.
View Article and Find Full Text PDFSingle or Dual Antiplatelet Therapy Improves One-Year Arteriovenous Graft Patency and Overall Survival.
Ann Vasc Surg
November 2024
Division of Vascular and Endovascular Surgery, Department of Surgery, St Louis University, St Louis, MO.
Article Synopsis
- * A study involving nearly 50,000 AVF and 12,688 AVG patients assessed the impact of different anti-thrombotic therapies, showing SAPT yielded better outcomes compared to no antiplatelet treatment.
- * Dual antiplatelet therapy (DAPT) also improved primary patency for AVG patients, while the combination of aspirin and anticoagulation showed no significant benefits and had worse survival outcomes for both AVF and AVG patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!